Literature DB >> 10366109

Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis.

S P Atamas1, V V Yurovsky, R Wise, F M Wigley, C J Goter Robinson, P Henry, W J Alms, B White.   

Abstract

OBJECTIVE: This study addresses the hypothesis that a profibrotic pattern of cytokines is produced in the lungs of patients with systemic sclerosis (SSc) and causes fibrosis.
METHODS: Using a reverse transcriptase-polymerase chain reaction technique, interleukin-4 (IL-4), IL-5, and interferon-gamma (IFNgamma) messenger RNA (mRNA) were measured in unseparated CD8+ and CD4+ bronchoalveolar lavage (BAL) cells from SSc patients and healthy controls. To confirm the results, CD8+ T cells were cloned from BAL fluids, and the pattern of cytokine mRNA made by these cells was determined. Serial pulmonary function tests were done.
RESULTS: BAL cells from healthy controls made IFNgamma mRNA, with no or little IL-4 or IL-5 mRNA. In contrast, BAL cells from the majority of SSc patients made IL-4 and/or IL-5 mRNA, with or without approximately equal amounts of IFNgamma mRNA. This pattern of cytokines was made by CD8+ T cells, which were increased in the lungs of these SSc patients. Patients whose BAL cells made this type 2 pattern of cytokine mRNA had a significant decline in forced vital capacity over time after the BAL, whereas patients whose BAL cells made IFNgamma mRNA alone did not. Both wild-type and an alternative splice variant of IL-4 mRNA were increased in BAL cells from SSc patients. Both forms of IL-4 stimulated alpha2(I) collagen mRNA in human dermal and lung fibroblasts.
CONCLUSION: The type 2 pattern of cytokine mRNA produced by BAL cells from SSc patients differs from unopposed IFNgamma production found in healthy BAL cells. This production of type 2 cytokine mRNA by CD8+ T cells is associated with a significant decline in lung function over time, which suggests a pathologic role for these T cells in interstitial fibrosis in SSc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366109     DOI: 10.1002/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  63 in total

Review 1.  Interleukin 4 in systemic sclerosis: not just an increase.

Authors:  S P Atamas; B White
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

Review 4.  The genetics of systemic sclerosis.

Authors:  Randall W Johnson; Monty B Tew; Frank C Arnett
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

5.  Intracellular cytokine repertoire in different T cell subsets from patients with sarcoidosis.

Authors:  M Möllers; S P Aries; D Drömann; B Mascher; J Braun; K Dalhoff
Journal:  Thorax       Date:  2001-06       Impact factor: 9.139

6.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

7.  Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement.

Authors:  Noha A Azab; Hanaa M Rady; Samar A Marzouk
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

8.  PKCalpha mediates CCL18-stimulated collagen production in pulmonary fibroblasts.

Authors:  Irina G Luzina; Kendrick Highsmith; Kerill Pochetuhen; Natalia Nacu; Jaladanki N Rao; Sergei P Atamas
Journal:  Am J Respir Cell Mol Biol       Date:  2006-04-06       Impact factor: 6.914

Review 9.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

10.  T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease.

Authors:  Francesco Boin; Umberto De Fanis; Susan J Bartlett; Fredrick M Wigley; Antony Rosen; Vincenzo Casolaro
Journal:  Arthritis Rheum       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.